

مجله علمي ابن سينا / اداره بهداشت و درمان نهاجا (سال ۹، شماره ۲، پايز ۱۳۸۵، مسلسل ۲۳)

B

B

B

(Polycolonial Antibody)

(Polyethilen Glycol)

(immortal)

Screening)

(method

(Hybridoma)

Elisa

RIA(Radio immunoassay)

B

(Restriction)

(Linker)

(vector)

PCR

(Passive)

(Selective Medium)

(FAD)

(Naked)

(conjugated)

()

Nacked

() HAT

CD₂₀ Rituxan .

(Non Hodgkin lymphoma)

VEGF

Avsttin

DNA

nutrient

mRNA

) CLL

campath

(Complementry DNA) cDNA

CD₅₂

(

(polymerase chain reaction) PCR

(single chain fragment variable) SCFV

Mylotarg

FDA

CD₃₃ calicheamicin

DNA

FDA

chimeric

Zevalin

Humaizad

Bexxar

FDA

1. Youngwoo SJ. Molecules and cells. Institute of Biotechnology, Korea, 2005.
2. Hyo Jeong Hong. Antibody engineering. Korea Research lab, 2005.
3. <http://www.covalab.com/beta/monoclonal> Antibodys.
4. Monoclonal antibody therapy available from: <http://www.American> cancer society (ACS).
5. <http://www.affitech.com/technology> troybodies. shtml.
6. <http://www.fda.gov/cder/drug/2005/sep>.
7. <http://www.FDA> Approved. MAb.loy/2006.

Monoclonal antibodies

Abstract:

Antibodies are proteins with a specific structure which enables them to bind to specific antigens.

Collectively known as "Immunoglobulins" (Ig).

Antibodies are produced by mature B cells (plasma cell) usually in response to infection or immunization. They are used to either neutralize pathogens or to bind them preventing them from migration so that they can undergo phagocytosis, removing the threat of contracting disease.

Monoclonal antibody therapy is a form of passive immunotherapy as the antibodies are made in large quantities outside the body.

Irandoost A.A, B.S.

IRIAF Health Administration

Key words: **Chemotherapy, Recombination, Hybridoma, monoclonal antibody**